Aptevo Shareholders Equity Per Share from 2010 to 2024

APVO Stock  USD 0.34  0.03  9.68%   
Aptevo Therapeutics Shareholders Equity Per Share yearly trend continues to be very stable with very little volatility. Shareholders Equity Per Share is likely to drop to 44.83. During the period from 2010 to 2024, Aptevo Therapeutics Shareholders Equity Per Share quarterly data regression pattern had sample variance of 1.7 M and median of  1,539. View All Fundamentals
 
Shareholders Equity Per Share  
First Reported
2010-12-31
Previous Quarter
47.18532819
Current Value
44.83
Quarterly Volatility
1.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aptevo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptevo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 538.6 K, Interest Expense of 43.1 M or Selling General Administrative of 19.2 M, as well as many indicators such as Price To Sales Ratio of 4.17, Dividend Yield of 0.0 or PTB Ratio of 0.16. Aptevo financial statements analysis is a perfect complement when working with Aptevo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

Latest Aptevo Therapeutics' Shareholders Equity Per Share Growth Pattern

Below is the plot of the Shareholders Equity Per Share of Aptevo Therapeutics over the last few years. It is Aptevo Therapeutics' Shareholders Equity Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptevo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Shareholders Equity Per Share10 Years Trend
Slightly volatile
   Shareholders Equity Per Share   
       Timeline  

Aptevo Shareholders Equity Per Share Regression Statistics

Arithmetic Mean1,500
Geometric Mean572.57
Coefficient Of Variation86.98
Mean Deviation1,202
Median1,539
Standard Deviation1,304
Sample Variance1.7M
Range2.9K
R-Value(0.93)
Mean Square Error257,910
R-Squared0.86
Slope(270.37)
Total Sum of Squares23.8M

Aptevo Shareholders Equity Per Share History

2024 44.83
2023 47.19
2022 154.47
2021 11.41
2020 215.32
2019 178.62
2018 832.45

About Aptevo Therapeutics Financial Statements

Aptevo Therapeutics investors utilize fundamental indicators, such as Shareholders Equity Per Share, to predict how Aptevo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Shareholders Equity Per Share 47.19  44.83 

Pair Trading with Aptevo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptevo Stock

  0.43KZR Kezar Life SciencesPairCorr
  0.34A Agilent Technologies Sell-off TrendPairCorr
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.24)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(2.51)
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.